Mortality was lower in diabetes patients given sitagliptin at admission for COVID-19, ACP practice points support remdesivir, acquired thrombophilia does not predict clots, cardiac arrest survival is low, and admissions for other conditions were
A risk calculator, genetic findings, and red blood cell distribution width helped predict severity of and death from COVID-19. Tocilizumab showed benefit, but a number of other treatments, including CPR, did not, according to recent research.
During the epidemic period of COVID-19, when seeing patients with neurologic manifestations, clinicians should suspect severe acute respiratory syndrome coronavirus 2 infection as a differential diagnosis to avoid delayed diagnosis
Several journal articles described recently implemented strategies for isolation, education, testing, visitors, and staff support, while others called for research collaboration and support for female hospitalists.
Recent studies showed that the risk of catching SARS-CoV-2 in a hospital is low for patients and varies by job and preventive measures for health care workers. A model and a serology study identified patients with worse outcomes from COVID-19.
This month's Q&A and Newman's Notions are also about the novel coronavirus.
More cases of the novel coronavirus disease (COVID-19) are being reported around the world, including in the U.S., and ACP and the CDC have both developed updated information for
Updates to the FDA's Coronavirus Treatment Acceleration Program webpage.
Steroids' effects varied by C-reactive protein level, clots occurred despite prophylaxis, and hydroxychloroquine and zinc were ineffective for COVID-19, according to newly published studies.
Researchers published evidence of re-infection with SARS-CoV-2, anticoagulation was associated with halved inpatient mortality, recommendations were made on pulmonary embolism in COVID-19, and the authorization for use of remdesivir was expanded.